Centre moves to bar retailers, wholesalers from advertising prescription drugs

What exactly is the Indian government proposing to change about advertising prescription drugs?

The government proposes extending advertising restrictions for potent prescription medicines beyond manufacturers. Under the proposed change, no Schedule H, Schedule H1 or Schedule X drug could be advertised without prior sanction from the Central Government. The aim is to strengthen oversight across the medicine supply chain and discourage unauthorized promotion.

The proposed amendment would operate under Rule 65 of the Drugs Rules, 1945. It would apply to every licence holder allowed to sell, stock, exhibit, offer for sale or distribute these medicines. That includes ordinary chemists, wholesalers, large distributors and online pharmacy platforms.

The draft rules were notified in the official gazette on 28 September. The government has invited objections and suggestions for 30 days before finalizing the amendment. If adopted, the rule would reduce the gap between restrictions on manufacturers and those on other businesses promoting prescription drugs.

What are Schedule H, Schedule H1 and Schedule X medicines, and why do they require strict controls?

Schedule H, Schedule H1 and Schedule X are categories of medicines subject to strict regulatory controls under India’s drug rules. The article describes them as covering potent substances that require medical oversight. They include certain antibiotics, anti-tuberculosis medicines, psychotropic medicines and habit-forming drugs.

These medicines are not meant to be promoted like ordinary consumer products. Their use needs appropriate supervision because the wrong medicine, dose or duration can create risks. The article specifically links unauthorized promotion with inappropriate self-medication and says safeguards are needed for prescription-only drugs.

The proposed rule would require prior Central Government sanction for any advertisement involving medicines in these schedules. This would extend scrutiny to sellers and distributors, not only manufacturers. The article does not provide the detailed legal definition of each schedule, but presents all three as tightly controlled categories requiring medical supervision.

How broad is the proposed rule— which retailers, wholesalers, distributors and online pharmacies would it cover?

The proposed rule is broad because it applies to all entities holding licences connected with selling or distributing the covered medicines. It is not limited to pharmaceutical companies that manufacture drugs. The government wants advertising controls to follow medicines through the wider supply chain.

In practical terms, the measure would include brick-and-mortar chemists, wholesalers, large distributors and online pharmacy platforms. It also covers licence holders that sell, stock, exhibit, offer for sale or distribute Schedule H, H1 or X medicines. These entities could not advertise the drugs without prior Central Government sanction.

This breadth addresses the loophole identified by the Drugs Technical Advisory Board. The proposed amendment would bring sellers and intermediaries under the same central advertising scrutiny as manufacturers. The government says this should discourage unauthorized promotion and reduce risks from inappropriate self-medication.

What regulatory loophole currently allows sellers and distributors to advertise these medicines even though manufacturers face restrictions?

The loophole comes from an uneven regulatory framework. Existing rules prohibit pharmaceutical manufacturers from advertising Schedule H, Schedule H1 and Schedule X medicines without prior Central Government sanction. However, the corresponding provisions do not explicitly cover businesses that retail, wholesale or distribute those medicines.

That means the restriction is clearly directed at manufacturers, while other licensed participants in the supply chain are not expressly named in the same advertising provision. These participants include chemists, wholesalers, distributors and online pharmacy platforms. The gap concerns promotion, not necessarily whether the products themselves are prescription medicines.

The proposed amendment would address the omission through Rule 65 of the Drugs Rules, 1945. It would state that no covered drug advertisement could be made without prior government sanction. The change follows DTAB recommendations that highlighted the absence of advertising provisions for distribution licence holders.

What could happen to patients if potent antibiotics, psychotropic drugs or habit-forming medicines are promoted without proper medical oversight?

Patients may be more likely to use potent medicines without appropriate medical supervision when sellers promote them improperly. The health ministry says the proposed amendment is intended to reduce risks associated with inappropriate self-medication. The article presents this as a central reason for tightening advertising controls.

The concern is especially important for medicines in the three schedules. They include certain critical antibiotics, anti-tuberculosis medicines, psychotropic medicines and habit-forming drugs. Promotion by retailers or distributors could make these prescription-only treatments appear easier to obtain or use without proper oversight, although the article does not specify individual patient outcomes.

The proposed rule is therefore preventive. By requiring Central Government sanction for advertisements, it seeks to discourage unauthorized promotion across the supply chain. The ministry expects stronger safeguards for medicines needing medical supervision. The final effect will depend on whether the draft is adopted after public and stakeholder consultation.

How will the proposed amendment become final, and what role can the public and pharmaceutical stakeholders play during the 30-day consultation?

The proposed amendment must pass through a consultation process before it becomes final. The draft rules have already been notified in the official gazette, but notification of a draft is not the same as completing the amendment. The government has invited responses from stakeholders and members of the public.

They have 30 days to send objections and suggestions. Pharmaceutical companies, retailers, distributors, online pharmacy businesses and other interested parties can use this period to comment on how the proposed advertising requirement would work. The article does not state a specific submission method or consultation deadline date.

After the prescribed period ends, the Central Government will consider submissions received within the allowed time. It will then decide how to proceed before finalizing the amendment. The proposal follows detailed consultations with the DTAB and recommendations from its 93rd meeting on 16 February.

What is a prescription-only medicine, and why is a doctor's supervision important when using it?

A prescription-only medicine is a drug that requires a medical professional’s direction before use. The doctor’s role is important because the medicine may need a specific choice, dose, duration or monitoring plan. In the article’s context, these medicines are treated as requiring appropriate medical supervision.

The covered categories include certain antibiotics, anti-tuberculosis medicines, psychotropic medicines and habit-forming drugs. The article describes them as potent substances and warns about risks linked to inappropriate self-medication. Advertising can influence people to seek or use a medicine without the oversight the treatment requires.

The proposed Indian rule would not simply ban every advertisement automatically. It would require prior sanction from the Central Government for advertisements of Schedule H, H1 and X medicines. The article’s stated purpose is to reinforce safeguards, discourage unauthorized promotion and reduce risks across the pharmaceutical supply chain.

Key Facts:

📌 The proposal requires central approval before covered prescription drugs can be advertised.

📌 The rule would extend beyond manufacturers to sellers and distributors.

📌 The draft amendment was notified in the official gazette on 28 September.

📌 The schedules include certain antibiotics and anti-tuberculosis medicines.

📌 Schedule H, H1 and X medicines require appropriate medical supervision.

📌 The categories include psychotropic and habit-forming drugs.

📌 Brick-and-mortar chemists would fall within the proposed rule.